drugset / Trial / NCT03272464
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma. The drugs involved in this study are: * Itacitinib (INCB039110) * Dabrafenib * Trametinib
Timeline
- Start
- 2019-05-29
- Primary completion
- 2019-07-24
- Completion
- 2019-12-27
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | — | Oral |
| Subject | Itacitinib | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | — | Oral |